8-K 1 form8-kcover_4qcall.htm 8-K Document
        




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 8-K
___________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 14, 2017
___________________

AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
___________________

Ireland  
(State or Other Jurisdiction
of Incorporation)

000-28508 
(Commission File Number)
98-1341933
(I.R.S. Employer
Identification No.)
 
Block 10-1,  
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland 
 (Address of Principal Executive Offices)
 


Not Applicable
(Zip Code)

 

Registrant’s telephone number, including area code: +353 1 485 1200
___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
•
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
•
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
•
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
•
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01 Other Events.
 

1
28866715

On February 14, 2017, Avadel Pharmaceuticals plc issued a press releases announcing that the Company will report its fourth quarter and full year 2016 financial results on Tuesday, March 7, 2017 before the market opens, a copy of which is furnished as Exhibits 99.1 to this current report on Form 8-K and is incorporated herein by reference.
  
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1
 
Press release of Avadel Pharmaceuticals plc dated as of February 14, 2017.
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Avadel Pharmaceuticals plc
By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary

Date: February 16, 2017
 
Exhibit Index
 
 
99.1
 
Press release of Avadel Pharmaceuticals plc dated as of February 14, 2017.


2
28866715